Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.46 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5100963 | 0.81 | USP30 (0.56) | USP30ACKR3NR1H4NPC1RAB9A | |
| SCHEMBL5097412 | 0.78 | LOXL2 (0.40) | NPC1RAB9AKMT2AUCHL1 | |
| SCHEMBL23507512 | 0.74 | CTSL (0.64) | SIGMAR1CTSLCTSBCTSKHCRTR1 | |
| SCHEMBL18986978 | 0.73 | USP30 (1.00) | USP30 | |
| SCHEMBL18986981 | 0.73 | USP30 (1.00) | USP30 | |
| SCHEMBL5093675 | 0.72 | HTT (0.56) | SIGMAR1 | |
| SCHEMBL5094075 | 0.72 | BCHE (0.55) | SIGMAR1CTSLCTSBCTSK | |
| SCHEMBL5106441 | 0.72 | USP30 (0.55) | USP30SIGMAR1 | |
| SCHEMBL5106500 | 0.71 | USP30 (0.52) | USP30NR1H4NPC1RAB9AKMT2A | |
| SCHEMBL5107052 | 0.71 | USP30 (0.52) | USP30NR1H4NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | claimed |
| US-7417062-B2 | e.g. N (S)-(1-Cyclohexylmethyl-pyrrolidine-2-ylmethyl)-3,4-dimethoxy-N-naphthalen-2-ylmethyl-benzamide; inhibit the binding of the SDF-1 (CXCL12) chemokine or I-TAC (CXCL11) to the chemokine receptor CCXCKR2; anticarcinogenic agent; breast, lymph nodes, bone marrow, and lungs cancer | CHEMOCENTRYX, INC. (US) | 2008-08-26 | — | — | US | disclosed |
| WO-2006038989-A1 | SUBSTITUTED ARYLAMIDES | CHEMOCENTRYX, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074071-A1 | Substituted arylamides | CHEMOCENTRYX, INC. (US) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074071-A1 | Substituted arylamides | AADAC, BRDT, BRPF3 | USP30 1703/4885SIGMAR1 2807/4885ACKR3 4347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.